Aptamers Against COVID-19: An Untested Opportunity

Mini Rev Med Chem. 2022;22(13):1708-1715. doi: 10.2174/1389557522666220112094951.

Abstract

Given the lack of success in the development of effective drugs to treat COVID-19, which show "game-changing" potential, it is necessary to explore drugs with different modes of action. Single mode-of-action drugs have not been succeeded in curing COVID-19, which is a highly complex disease. This is the case for direct antivirals and anti-inflammatory drugs, both of which treat different phases of the disease. Aptamers are molecules that deliver different modes of action, allowing their effects to be bundled, which, when combined, support their therapeutic efficacy. In this minireview, we summarise the current activities in the development of aptamers for the treatment of COVID-19 and long-COVID. A special emphasis is placed on the capability of their multiple modes of action, which is a promising approach for treating complex diseases such as COVID-19.

Keywords: Aptamer; BC 007; COVID-19; SARS-CoV-2; long-COVID-19; multiple modes-of-action.

MeSH terms

  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • COVID-19 Drug Treatment*
  • COVID-19* / complications
  • Drug Repositioning
  • Humans
  • Post-Acute COVID-19 Syndrome
  • SARS-CoV-2

Substances

  • Antiviral Agents